|
1
|
Di Renzo MF, Narsimhan RP, Olivero M,
Bretti S, Giordano S, Medico E, Gaglia P, Zara P and Comoglio PM:
Expression of the Met/HGF receptor in normal and neoplastic human
tissues. Oncogene. 6:1997–2003. 1991.PubMed/NCBI
|
|
2
|
Comoglio PM and Boccaccio C: The HGF
receptor family: Unconventional signal transducers for invasive
cell growth. Genes Cells. 1:347–354. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jeffers M, Rong S and Vande Woude GF:
Hepatocyte growth factor/scatter factor-Met signaling in
tumorigenicity and invasion/metastasis. J Mol Med (Berl).
74:505–513. 1996. View Article : Google Scholar
|
|
4
|
Pennacchietti S, Michieli P, Galluzzo M,
Mazzone M, Giordano S and Comoglio PM: Hypoxia promotes invasive
growth by transcriptional activation of the met protooncogene.
Cancer Cell. 3:347–361. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kuniyasu H, Yasui W, Kitadai Y, Yokozaki
H, Ito H and Tahara E: Frequent amplification of the c-met gene in
scirrhous type stomach cancer. Biochem Biophys Res Commun.
189:227–232. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kijima Y, Hokita S, Yoshinaka H, Itoh T,
Koriyama C, Eizuru Y, Akiba S and Aikou T: Amplification and
overexpression of c-met gene in Epstein-Barr virus-associated
gastric carcinomas. Oncology. 62:60–65. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakazawa K, Dobashi Y, Suzuki S, Fujii H,
Takeda Y and Ooi A: Amplification and overexpression of c-erbB-2,
epidermal growth factor receptor, and c-met in biliary tract
cancers. J Pathol. 206:356–365. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miller CT, Lin L, Casper AM, Lim J, Thomas
DG, Orringer MB, Chang AC, Chambers AF, Giordano TJ, Glover TW, et
al: Genomic amplification of MET with boundaries within fragile
site FRA7G and upregulation of MET pathways in esophageal
adenocarcinoma. Oncogene. 25:409–418. 2006.
|
|
9
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lutterbach B, Zeng Q, Davis LJ, Hatch H,
Hang G, Kohl NE, Gibbs JB and Pan BS: Lung cancer cell lines
harboring MET gene amplification are dependent on Met for growth
and survival. Cancer Res. 67:2081–2088. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nakamura T, Teramoto H and Ichihara A:
Purification and characterization of a growth factor from rat
platelets for mature parenchymal hepatocytes in primary cultures.
Proc Natl Acad Sci USA. 83:6489–6493. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Birchmeier C and Gherardi E: Developmental
roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends
Cell Biol. 8:404–410. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Birchmeier C, Birchmeier W, Gherardi E and
Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol
Cell Biol. 4:915–925. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ullrich A and Schlessinger J: Signal
transduction by receptors with tyrosine kinase activity. Cell.
61:203–212. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rodrigues GA and Park M:
Autophosphorylation modulates the kinase activity and oncogenic
potential of the Met receptor tyrosine kinase. Oncogene.
9:2019–2027. 1994.PubMed/NCBI
|
|
16
|
Ma PC, Tretiakova MS, Nallasura V,
Jagadeeswaran R, Husain AN and Salgia R: Downstream signalling and
specific inhibition of c-MET/HGF pathway in small cell lung cancer:
Implications for tumour invasion. Br J Cancer. 97:368–377. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Henne WM, Buchkovich NJ and Emr SD: The
ESCRT pathway. Dev Cell. 21:77–91. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yarden Y: The EGFR family and its ligands
in human cancer signaling mechanisms and therapeutic opportunities.
Eur J Cancer. 37:3–8. 2001. View Article : Google Scholar
|
|
19
|
Nishimura Y, Takiguchi S, Ito S and Itoh
K: Evidence that depletion of the sorting nexin 1 by siRNA promotes
HGF-induced MET endocytosis and MET phosphorylation in a
gefitinib-resistant human lung cancer cell line. Int J Oncol.
44:412–426. 2014.
|
|
20
|
Nishimura Y, Takiguchi S, Ito S and Itoh
K: EGF-stimulated AKT activation is mediated by EGFR recycling via
an early endocytic pathway in a gefitinib-resistant human lung
cancer cell line. Int J Oncol. 46:1721–1729. 2015.PubMed/NCBI
|
|
21
|
Hyuga S, Hyuga M, Yamagata S, Yamagata T
and Hanawa T: Mao-to, a Kampo medicine, inhibits migration of
highly metastatic osteosarcoma cells. J Trad Med. 21:174–181.
2004.
|
|
22
|
Hyuga S, Hyuga M, Nakanishi H, Ito H,
Watanabe K, Oikawa T and Hanawa T: Maoto, Kampo medicine,
suppresses the metastatic potential of highly metastatic
osteosarcoma cells. J Trad Med. 24:51–58. 2007.
|
|
23
|
Hyuga S, Shiraishi M, Hyuga M, Goda Y and
Hanawa T: Ephedrae herba, a major component of maoto, inhibits the
HGF-induced motility of human breast cancer MDA-MB-231 cells
through suppression of c-Met tyrosine phosphorylation and c-Met
expression. J Trad Med. 28:128–138. 2011.
|
|
24
|
Hyuga S and Hanawa T: Basic research on
the use of Kampo medicines to protect against cancer recurrence and
metastasis. J Trad Med. 30:19–26. 2013.
|
|
25
|
Amakura Y, Yoshimura M, Yamakami S,
Yoshida T, Wakana D, Hyuga M, Hyuga S, Hanawa T and Goda Y:
Characterization of phenolic constituents from ephedra herb
extract. Molecules. 18:5326–5334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hyuga S, Hyuga M, Yoshimura M, Amakura Y,
Goda Y and Hanawa T: Herbacetin, a constituent of ephedrae herba,
suppresses the HGF-induced motility of human breast cancer
MDA-MB-231 cells by inhibiting c-Met and Akt phosphorylation.
Planta Medica. 79:1525–1530. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nishimura Y, Higaki M and Kato K:
Identification of a precursor form of cathepsin D in microsomal
lumen: Characterization of enzymatic activation and proteolytic
processing in vitro. Biochem Biophys Res Commun. 148:335–343. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nishimura Y, Kawabata T and Kato K:
Identification of latent procathepsins B and L in microsomal lumen:
Characterization of enzymatic activation and proteolytic processing
in vitro. Arch Biochem Biophys. 261:64–71. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nishimura Y, Bereczky B and Ono M: The
EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis
of EGFR via the early/late endocytic pathway in non-small cell lung
cancer cell lines. Histochem Cell Biol. 127:541–553. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nishimura Y, Yoshioka K, Bereczky B and
Itoh K: Evidence for efficient phosphorylation of EGFR and rapid
endocytosis of phosphorylated EGFR via the early/late endocytic
pathway in a gefitinib-sensitive non-small cell lung cancer cell
line. Mol Cancer. 7:422008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nishimura Y, Yoshioka K, Takiguchi S,
Bereczky B, Nakabeppu Y and Itoh K: A role for SNX1 in the
regulation of EGF-dependent phosphorylated EGFR endocytosis via the
early/late endocytic pathway in a gefitinib-sensitive human lung
cancer cells. Curr Signal Transduct Ther. 6:383–395. 2011.
View Article : Google Scholar
|
|
32
|
Nishimura Y, Takiguchi S, Yoshioka K,
Nakabeppu Y and Itoh K: Silencing of SNX1 by siRNA stimulates the
ligand-induced endocytosis of EGFR and increases EGFR
phosphorylation in gefitinib-resistant human lung cancer cell
lines. Int J Oncol. 41:1520–1530. 2012.PubMed/NCBI
|
|
33
|
Worby CA and Dixon JE: Sorting out the
cellular function of sorting nexins. Nat Rev Mol Cell Biol.
3:919–931. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kurten RC, Cadena DL and Gill GN: Enhanced
degradation of EGF receptors by a sorting nexin, SNX1. Science.
272:1008–1010. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kornfeld S and Mellman I: The biogenesis
of lysosomes. Annu Rev Cell Biol. 5:483–525. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sandoval IV, Arredondo JJ, Alcalde J,
Gonzalez-Noriega A, Vandekerckhove J, Jimenez MA and Rico M: The
residues Leu (Ile) 475-Ile (Leu) 476, contained in the extended
carboxyl cytoplasmic tail, are critical for targeting of the
resident lysosomal membrane protein LIMPII to lysosomes. J Biol
Chem. 269:6622–6631. 1994.PubMed/NCBI
|
|
37
|
Bean J, Brennan C, Shih JY, Riely G, Viale
A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al: MET
amplification occurs with or without T790M mutations in EGFR mutant
lung tumors with acquired resistance to gefitinib or erlotinib.
Proc Natl Acad Sci USA. 104:20932–20937. 2007. View Article : Google Scholar : PubMed/NCBI
|
